Brief: Adamis Pharmaceuticals’ Clinical Study Assessing Tempol For The Treatment Of COVID-19 Surpasses Enrollment Expectations

DMK Pharmaceuticals

28/02/2022 12:46

Feb 28 (Reuters) - Adamis Pharmaceuticals Corp  ADMP.O :
    * ADAMIS PHARMACEUTICALS’ CLINICAL STUDY ASSESSING TEMPOL
FOR THE
TREATMENT OF COVID-19 SURPASSES ENROLLMENT EXPECTATIONS
    * ADAMIS PHARMACEUTICALS - BASED ON ANALYSIS OF DATA, DSMB
DETERMINED THAT STUDY CAN CONTINUE, AS THERE WERE NO SAFETY OR
CLINICAL CONCERNS IDENTIFIED
    * ADAMIS PHARMACEUTICALS CORP - DATA FROM FIRST 50 SUBJECTS
WILL
BE REVIEWED AGAIN IN MARCH

Source text for Eikon:  ID:nGNX7z5CS5 
Further company coverage:  ADMP.O 

 ((Reuters.Briefs@thomsonreuters.com;))